Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3256-3263

  Sparano, Joseph A ^a   Vrdoljak, Eduard ^a   Rixe, Oliver ^a   Xu, Binghe ^a   Manikhas, Alexey ^a   Medina, Carlos ^a   Da Costa, Susanne Crocamo Ventilari ^a   Ro, Jungsil ^a   Rubio, Gonzalo ^a   Rondinon, Monica ^a   Manga, Gumersindo Perez ^a   Peck, Ronald ^a   Poulart, Valerie ^a   Conte, Pierfranco ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; IXABEPILONE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUOROURACIL; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HAZARD RATIO; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG RESISTANCE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PERIPHERAL NERVOUS SYSTEM DISEASES; RETREATMENT; TAXOIDS;

EID: 77954752064     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.4244     Document Type: Article

References (27)

1. Surveillance Epidemiology and End Results: Estimated new cancer cases and deaths for 2006. http://seer.cancer.gov/csr/1975-2003/results-resulsingle/ resulsect-resul01-resultable.01.pdf
2. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999 (Pubitemid 29075232)
3. Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004 (Pubitemid 38220770)
4. Lee JJ, Swain SM: Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 32:S22-S26, 2005 (Pubitemid 41785443)
5. Fumoleau P, Coudert B, Isambert N, et al: Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18:v9-v15, 2007 (suppl 5)
6. Lee FY, Borzilleri R, Fairchild CR, et al: Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 63:157-166, 2008
7. Lee FY, Shen H, Lee H, et al: Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III β tubulin and breast cancer resistance protein. Eur J Cancer 6:219, 2008 (abstr)
8. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007 (Pubitemid 47310876)
9. Roché H, Yelle L, Cognetti F, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-3420, 2007 (Pubitemid 47310877)
10. Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406, 2007 (Pubitemid 47310875)
11. Lee FY, Camuso A, Castenada C, et al: Preclinical efficacy evaluation of ixabepilone (BMS 247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24:597s, 2006 (abstr 12017)
12. Bunnell C, Vahdat L, Schwartzberg L, et al: Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8:234-241, 2008 (Pubitemid 351962144)
13. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007 (Pubitemid 350232252)
14. Thomas ES: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 26:2223, 2008
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Pivot X, Dufresne A, Villanueva C: Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 7:543-549, 2007 (Pubitemid 46725246)
17. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001 (Pubitemid 32952493)
18. Oshaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001 (Pubitemid 32994752)
19. Hortobagyi G, Perez E, Vrdoljak E, et al: Analysis of overall survival among patients with metastatic breast cancer receiving either ixabepilone plus capecitabine or capecitabine alone and a review of results from two randomized phase III trials. Presented at Am Soc Clin Oncol Breast Cancer Proceedings, Washington, DC, September 5-7, 2008 (abstr 186)
20. National Comprehensive Cancer Network: Breast Cancer Guidelines V.2.2010. http://www.nccn.org/interactive/default.asp#breast
21. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
22. Martín M, Ruiz A, Munoz M, et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Res Group (GEICAM) trial. Lancet Oncol 8:219-225, 2007 (Pubitemid 46291704)
23. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
24. Petrelli F, Cabiddu M, Cazzaniga ME, et al: Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 13:373-381, 2008 (Pubitemid 351679916)
25. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al: Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:1980-1986, 2008
26. Sargent DJ, Hayes DF: Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol 26:1922-1923, 2008
27. Conte P, Roche H, Perez E, et al: Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. Cancer Res 69:6114, 2009